139 related articles for article (PubMed ID: 7105004)
1. Immunological and pharmacological characterization of poly-DL-alanyl-modified Erwinia carotovora L-asparaginase.
Uren JR; Hargis BJ; Beardsley P
Cancer Res; 1982 Oct; 42(10):4068-71. PubMed ID: 7105004
[TBL] [Abstract][Full Text] [Related]
2. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.
Uren JR; Ragin RC
Cancer Res; 1979 Jun; 39(6 Pt 1):1927-33. PubMed ID: 376113
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates.
Zhang YQ; Zhou WL; Shen WD; Chen YH; Zha XM; Shirai K; Kiguchi K
J Biotechnol; 2005 Nov; 120(3):315-26. PubMed ID: 16102867
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, physicochemical and immunological properties of oxidized inulin-L-asparaginase bioconjugate.
Tabandeh MR; Aminlari M
J Biotechnol; 2009 May; 141(3-4):189-95. PubMed ID: 19433225
[TBL] [Abstract][Full Text] [Related]
5. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.
Kamisaki Y; Wada H; Yagura T; Matsushima A; Inada Y
J Pharmacol Exp Ther; 1981 Feb; 216(2):410-4. PubMed ID: 7007618
[TBL] [Abstract][Full Text] [Related]
6. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of biosynthetic human LysPro insulin compared to native-sequence human and purified porcine insulins in rhesus monkeys immunized over a 6-week period.
Zwickl CM; Smith HW; Zimmermann JL; Wierda D
Arzneimittelforschung; 1995 Apr; 45(4):524-8. PubMed ID: 7779155
[TBL] [Abstract][Full Text] [Related]
9. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
[TBL] [Abstract][Full Text] [Related]
10. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
Albertsen BK; Schrøder H; Jakobsen P; Avramis VI; Müller HJ; Schmiegelow K; Carlsen NT
Med Pediatr Oncol; 2002 May; 38(5):310-6. PubMed ID: 11979454
[TBL] [Abstract][Full Text] [Related]
11. Comparative experimental evaluation of immunodepressive and toxic effects of L-asparaginase (NSC-109229) from Escherichia coli and from Erwinia carotovora.
Cavanna M; Celle G; Dodero M; Picciotto A; Pannacciulli I; Brambilla G
Cancer Treat Rep; 1976 Mar; 60(3):255-7. PubMed ID: 769978
[No Abstract] [Full Text] [Related]
12. Purification and preliminary characterization of L-asparaginase from Erwinia aroideae NRRL B-138.
Tiwari N; Dua RD
Indian J Biochem Biophys; 1996 Oct; 33(5):371-6. PubMed ID: 9029817
[TBL] [Abstract][Full Text] [Related]
13. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.
Riccardi R; Holcenberg JS; Glaubiger DL; Wood JH; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4554-8. PubMed ID: 6895481
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
Roberts J; Schmid FA; Old LJ; Stockert E
Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
16. Date palm pollen allergoid: characterization of its chemical-physical and immunological properties.
Mistrello G; Harfi H; Roncarolo D; Kwaasi A; Zanoni D; Falagiani P; Panzani R
Int Arch Allergy Immunol; 2008; 145(3):224-30. PubMed ID: 17914274
[TBL] [Abstract][Full Text] [Related]
17. Modification of L-asparaginase from Erwinia carotovora using human serum albumin.
Nerkar DP; Gangadharan M
Mol Biother; 1989; 1(3):152-4. PubMed ID: 2604913
[TBL] [Abstract][Full Text] [Related]
18. Toxic and immunodepressive effects of L-asparaginase from E. coli and from Erwinia carotovora following chronic administration in rats.
Celle G; Dodero M; Cuneo P; Picciotto A; Brambilla G; Cavanna M; Pannaciulli I
Arzneimittelforschung; 1977; 27(11):2046-50. PubMed ID: 341899
[TBL] [Abstract][Full Text] [Related]
19. Modified pharmacokinetics of I-asparaginase from E coli by formation of specific antibodies to I-Asparaginase of different immunoglobulin classes in children with acute lymphocytic leukemia.
Wahn V; Fabry U; Körholz D; Reinhardt D; Jürgens H; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):303-11. PubMed ID: 6377216
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional insights into Erwinia carotovora L-asparaginase.
Papageorgiou AC; Posypanova GA; Andersson CS; Sokolov NN; Krasotkina J
FEBS J; 2008 Sep; 275(17):4306-16. PubMed ID: 18647344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
